These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 10586358

  • 1. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
    Taue R, Kanayama H, Kagawa S.
    Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
    [Abstract] [Full Text] [Related]

  • 2. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
    Berruti A, Cerutti S, Fasolis G, Sperone P, Tarabuzzi R, Bertetto O, Pagani G, Zolfanelli R, Pallotti S, Bumma C, Fontana D, Rosseti SR, Dogliotti L, Angeli A.
    Anticancer Res; 1997 Oct; 17(6D):4697-702. PubMed ID: 9494591
    [Abstract] [Full Text] [Related]

  • 3. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [Abstract] [Full Text] [Related]

  • 4. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A, Francini G.
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M, Noda S.
    J Urol; 2001 Sep 01; 166(3):1106-10. PubMed ID: 11490307
    [Abstract] [Full Text] [Related]

  • 14. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA, Lange PH, Janknegt RA, Abbou CC, deGery A.
    J Urol; 1997 Apr 01; 157(4):1329-34. PubMed ID: 9120932
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 01; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 01; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
    Miyake H, Hara I, Yamazaki H, Eto H.
    Oncol Rep; 2005 Sep 01; 14(3):673-6. PubMed ID: 16077973
    [Abstract] [Full Text] [Related]

  • 18. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T, Kinjo M, Nutahara K, Higashihara E.
    Int J Urol; 2006 Sep 01; 13(9):1197-201. PubMed ID: 16984552
    [Abstract] [Full Text] [Related]

  • 19. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ, BAUS Section of Oncology Cancer Registry.
    Cancer; 2003 Dec 01; 98(11):2362-7. PubMed ID: 14635070
    [Abstract] [Full Text] [Related]

  • 20. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE.
    J Natl Cancer Inst; 2005 Jan 05; 97(1):59-69. PubMed ID: 15632381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.